Breakthrough Gene Therapy Offers Hope for Severe Developmental Epilepsy in Children
On Jun. 27, 2023, researchers from Tel Aviv University announced they have developed an innovative gene therapy that…
-
-
Moderna finalized agreement with Government of the Republic of Kenya to establish an mRNA manufacturing facility
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
-
Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & Adolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
-
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
-
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
-
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
-
EMA accepted Moderna’s conditional Marketing Authorization filing for omicron BA.4/BA.5 targeting bivalent COVID-19 vaccine
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
-
Moderna completed application to U.S. FDA for EUA of omicron-targeting bivalent Covid-19 booster vaccine
On Aug. 22, 2022, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of Moderna…
-
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
-
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
-
International team created first complete fruit fly cell atlas
On Mar. 9, 2022, Harvard Medical School announced that an international research team had completed an atlas of…
-
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
-
Moderna announced MOU with Government of Kenya to establish first mRNA manufacturing facility on the continent of Africa
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
-
Innovation Pharmaceuticals reported additional findings from Brilacidin phase 2 COVID-19 tial results
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
-
Agriculture | Biotechnology | CRISPR | Genomics | USDA
Yield10 Bioscience Field Test Results Show Seed Oil Content Increase in Camelina and Canola
On Mar. 1, 2022, Yield10 Bioscience announced that 2021 field test results showed that the trait C3020 tested…
-
Moderna and Thermo Fisher Scientific announced long-term strategic collaboration
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
-
Scientists regrow frog’s lost leg
On Jan. 26, 2022, scientists at Tufts and Harvard University’s Wyss Institute reported they were able to trigger…
-
Moderna launched AI Academy in partnership with Carnegie Mellon University
On Dec. 9, 2021, Moderna announced the launch of its Artificial Intelligence Academy, an innovative initiative that will…
-
Innovation Pharmaceuticals conducted full data analysis of phase 2 brilacidin COVID-19 trial results to support inclusion in Government-sponsored trials
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
-
Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.
On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…
-
Moderna announced submission of initial data to U.S. FDA for Its COVID-19 vaccine booster
On Sept. 1, 2021, Moderna announced it had initiated its submission to the U.S. Food and Drug Administration…
-
Moderna completed submission of BLA to the Food and Drug Administration for its COVID-19 vaccine
On Aug. 25, 2021, Moderna announced it had completed the rolling submission process for its Biologics License Application…
-
Collaboration created world’s largest browsable resource linking rare protein-coding genetic variants to human disease
On Jul. 8, 2021, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human…
-
Disease | FDA | Neurology | Therapeutics
Eisai and Biogen announced FDA granted Breakthrough Therapy Designation for Lecanemab for treatment of Alzheimer’s disease
On Jun. 23, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
-
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA granted accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment
On Jun. 7, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
-
Moderna announced expansion of its manufacturing technology center in Massachusetts
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
-
Moderna announced shipment of 100 millionth dose of its COVID-19 vaccine to the U.S. Government
On Mar. 29, 2021, Moderna announced that the Company has shipped the 100-millionth dose of its COVID-19 vaccine…
-
First participants dosed in Moderna phase 1 study evaluating mRNA-1283 next generation COVID-19 vaccine
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
-
Innovation Pharma’s COVID-19 drug candidate Brilacidin among top three percent predicted most effective against SARS-CoV-2
On Mar. 10, 2021, Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report that a Machine…
